Table 1. Baseline demographic data of the study patients.
| Hypervascular HCC only (Group A) | Hypovascular nodulesco-existing with hypervascular HCC (Group B) | P | |
|---|---|---|---|
| Patients, n | 107 | 45 | |
| Gender, n (%) | |||
| Male | 79 (74) | 31 (69) | 0.555 |
| Female | 28 (26) | 14 (31) | |
| Age in years, n (%) | |||
| ≤ 67 | 58 (54) | 20 (44) | 0.291 |
| > 67 | 49 (46) | 25 (56) | |
| Median (range) | 67 (41–80) | 69 (45–85) | |
| Child–Pugh class, n (%) | |||
| A | 87 (81) | 32 (71) | 0.197 |
| B | 20 (19) | 13 (29) | |
| HBs-Ag positive, n (%) | |||
| Absent | 94 (88) | 44 (98) | 0.066 |
| Present | 13 (12) | 1 (2) | |
| HCV-Ab positive, n (%) | |||
| Absent | 20 (19) | 6 (13) | 0.488 |
| Present | 87 (81) | 39 (87) | |
| Single hypervascular HCC, ≤ 20 mm, n (%) | |||
| Absent | 56 (52) | 28 (62) | 0.288 |
| Present | 51 (48) | 17 (38) | |
| AFP, ng/ml, n (%) | |||
| ≤ 100 | 85 (79) | 39 (87) | 0.364 |
| > 100 | 22 (21) | 6 (13) | |
| Median (range) | 18.4 (1.8–1997.2) | 15.0 (3.0–1315.0) | |
| Initial local therapy, n (%) | |||
| RFA | 62 (58) | 27 (60) | 0.858 |
| PEI | 45 (42) | 18 (40) |
Abbreviations: HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; HCC, hepatocellular carcinoma; AFP, alfa fetoprotein; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection.